Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Nano- and Micro-Technologies for the Treatment of Type-1 Diabetes
share announcement

Nano- and Micro-Technologies for the Treatment of Type-1 Diabetes

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (10 February 2023) | Viewed by 3234

Special Issue Editors

Dr. Rosita Primavera

E-Mail Website
Guest Editor
Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, CA 94304, USA
Interests: cellular and molecular biotechnologies; nano- and micro-drug delivery systems (DDS); diabetes; control released of insulin
Prof. Dr. Longhai Wang

E-Mail Website
Guest Editor
CAS Key Laboratory of Soft Matter Chemistry, Department of Polymer Science and Engineering, University of Science and Technology of China, Hefei 230026, China
Interests: biomedical polymers and biomaterials; biomedical engineering and biological modelling; cell delivery and cell therapy; gene delivery and gene therapy

Special Issue Information

Dear Colleagues,

Diabetes is a metabolic disease characterized by elevated blood glucose levels (BGLs) and the inability to maintain BGL homeostasis. Specifically, type 1 diabetic patients cannot produce insulin as a result of autoimmune destruction of beta cells within the pancreas. Current treatment strategies consist of multiple, daily injections of insulin or transplantation of either the whole pancreas or isolated pancreatic islets. While there are different forms of insulin with tunable pharmacokinetics (fast, intermediate, and long acting), improper dosing continues to be a major limitation often leading to complications resulting from either hyper- or hypoglycemia. On the other hand, islet transplantation is a promising strategy but requires multiple donors per patient. and post-transplantation islet survival is impaired by inflammation and suboptimal revascularization. Nano- and micro-technologies in diabetes research have facilitated the development of novel glucose measurement and insulin delivery modalities which can dramatically improve the quality of life for diabetics and contribute to realize an artificial pancreas-like system. The scope of this Special Issue is to gather recent progress in the field of diabetes research at its interface with nano- and micro-technologies.

Dr. Rosita Primavera
Prof. Dr. Longhai Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes
  • glucose sensor
  • nanotechnology
  • microparticles
  • insulin

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 10646 KiB  
Article
Nanothin Conformal Coating with Poly(N-vinylpyrrolidone) and Tannic Acid (PVPON/TA) Preserves Murine and Human Pancreatic Islets Function
by Kateryna Polishevska, Sandra Kelly, Purushothaman Kuppan, Karen L. Seeberger, Saloni Aggarwal, Joy Paramor, Larry D. Unsworth, Hubert M. Tse, Gregory S. Korbutt and Andrew R. Pepper
Pharmaceutics 2023, 15(4), 1137; https://doi.org/10.3390/pharmaceutics15041137 - 4 Apr 2023
Cited by 2 | Viewed by 1533
Abstract
Beta cell replacement therapies can restore glycemic control to select individuals living with type 1 diabetes. However, the obligation of lifelong immunosuppression restricts cell therapies from replacing exogenous insulin administration. Encapsulation strategies can reduce the inherent adaptive immune response; however, few are successfully [...] Read more.
Beta cell replacement therapies can restore glycemic control to select individuals living with type 1 diabetes. However, the obligation of lifelong immunosuppression restricts cell therapies from replacing exogenous insulin administration. Encapsulation strategies can reduce the inherent adaptive immune response; however, few are successfully translated into clinical testing. Herein, we evaluated if the conformal coating of islets with poly(N-vinylpyrrolidone) (PVPON) and tannic acid (TA) (PVPON/TA) could preserve murine and human islet function while conferring islet allograft protection. In vitro function was evaluated using static glucose-stimulated insulin secretion, oxygen consumption rates, and islet membrane integrity. In vivo function was evaluated by transplanting human islets into diabetic immunodeficient B6.129S7-Rag1tm1Mom/J (Rag-/-) mice. The immunoprotective capacity of the PVPON/TA-coating was assessed by transplanting BALB/c islets into diabetic C57BL/6 mice. Graft function was evaluated by non-fasting blood glucose measurements and glucose tolerance testing. Both coated and non-coated murine and human islets exhibited indistinguishable in vitro potency. PVPON/TA-coated and control human islets were able to restore euglycemia post-transplant. The PVPON/TA-coating as monotherapy and adjuvant to systemic immunosuppression reduced intragraft inflammation and delayed murine allograft rejection. This study demonstrates that PVPON/TA-coated islets may be clinically relevant as they retain their in vitro and in vivo function while modulating post-transplant immune responses. Full article
(This article belongs to the Special Issue Nano- and Micro-Technologies for the Treatment of Type-1 Diabetes)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop